BYOOVIZ — Total Revenue
Biogen BYOOVIZ — Total Revenue decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $8.90M to $0.00. Over 3 years (FY 2022 to FY 2025), BYOOVIZ — Total Revenue shows an upward trend with a 96.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration and adoption of the biosimilar, while a decrease may signal increased competition or pricing pressure in the ophthalmology market.
Detailed definition
This metric represents the total gross sales generated from the commercialization of the specific biosimilar product wit...
Peer comparison
Comparable to biosimilar or generic product revenue lines reported by other pharmaceutical companies, often evaluated based on market share capture relative to the reference drug.
biib_segment_byooviz_total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $500.00K | $700.00K | $3.10M | $8.60M | $7.00M | $6.90M | $9.20M | $5.60M | $13.70M | $8.00M | $9.30M | $8.90M | $8.60M | $7.00M | $7.90M | $0.00 |
| QoQ Change | — | — | — | — | +40.0% | +342.9% | +177.4% | -18.6% | -1.4% | +33.3% | -39.1% | +144.6% | -41.6% | +16.3% | -4.3% | -3.4% | -18.6% | +12.9% | -100.0% |
| YoY Change | — | — | — | — | — | — | — | >999% | +885.7% | +196.8% | -34.9% | +95.7% | +15.9% | +1.1% | +58.9% | -37.2% | -12.5% | -15.1% | -100.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's byooviz — total revenue?
- Biogen (BIIB) reported byooviz — total revenue of $0.00 in Q1 2026.
- How has Biogen's byooviz — total revenue changed year-over-year?
- Biogen's byooviz — total revenue decreased by 100.0% year-over-year, from $8.90M to $0.00.
- What is the long-term trend for Biogen's byooviz — total revenue?
- Over 3 years (2022 to 2025), Biogen's byooviz — total revenue has grown at a 96.0% compound annual growth rate (CAGR), from $4.30M to $32.40M.
- What does byooviz — total revenue mean?
- The total sales revenue generated from the company's specific biosimilar ophthalmology product.